AFFIMED THERAPEUTICS AG has a total of 40 patent applications. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and biotechnology are BERNETT MATTHEW J, LAVA THERAPEUTICS B V and AGOMAB THERAPEUTICS BVBA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Australia | 6 | |
#4 | Canada | 5 | |
#5 | United States | 5 | |
#6 | Brazil | 2 | |
#7 | China | 2 | |
#8 | Japan | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Little Melvyn | 33 |
#2 | Le Gall Fabrice | 24 |
#3 | Reusch Uwe | 23 |
#4 | Kipriyanov Sergey | 17 |
#5 | Knackmuss Stefan | 12 |
#6 | Hoffmann Karin | 10 |
#7 | Roettgen Peter | 9 |
#8 | Buettner Claudia | 6 |
#9 | Kiprijanov Sergej | 5 |
#10 | Moldenhauer Gerhard | 5 |
Publication | Filing date | Title |
---|---|---|
EP2982693A1 | CD3 binding domain | |
EP2930188A1 | Trifunctional antigen-binding molecule | |
CN103687879A | Multivalent antigen-binding FV molecule | |
EP1709972A1 | Use of an antibody against the laminin receptor or laminin receptor precursor for the diagnosis of cancer | |
EP1354600A1 | Antibody combination useful for tumor therapy | |
EP1314741A1 | Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof | |
EP1300419A1 | Antibody of human origin for inhibiting thrombocyte aggregation | |
EP1293514A1 | Multimeric single chain tandem Fv-antibodies |